Anti-Aging · Reference
Hexarelin for Women: What Has and Has Not Been Studied
This page covers what hexarelin is, what research has and has not looked at, the considerations that change for women, menopause and sleep, side effects, and how Pepti supplies it. For the full reference, see what is hexarelin.
Treatments mentioned
No hexarelin study in the published research Pepti draws on reports results for women separately, and the adult studies whose participants are described by sex were all in men. What is established applies to the molecule rather than to either sex: each dose releases a pulse of growth hormone with a smaller, brief rise in prolactin, ACTH and cortisol, and the only sustained adult course, sixteen weeks of twice-daily injections, found no change in lean mass, body fat or bone density. For women, the practical differences are the prolactin pulse, pregnancy and breastfeeding (it is not used), and the fact that growth hormone peptides have been shown in another trial to act differently in women. Compounded hexarelin is not FDA approved.
This page covers what hexarelin is, what research has and has not looked at, the considerations that change for women, menopause and sleep, side effects, and how Pepti supplies it. For the full reference, see what is hexarelin.
Hexarelin for Women
The short answer
| Question | What the live research shows | Strength of evidence |
|---|---|---|
| Has hexarelin been studied in women specifically? | No study in the live research reports women separately | None |
| Does it raise growth hormone? | Yes, in every adult group studied, by every route | Well established, mostly in men |
| Does it raise prolactin and cortisol? | Briefly with each dose; 24-hour totals unchanged in a study of young men | Human, small |
| Does it change body composition? | The one sixteen-week course found no change in lean mass, fat or bone density | Human, small; the result was null |
| Do growth hormone peptides act the same in women? | Not necessarily: in a 1997 trial of a GHRH analogue, lean mass and insulin sensitivity changed in men only | One small trial, of a different molecule |
| Menopause symptoms | Not studied; hexarelin is not hormone therapy | None |
| Pregnancy or breastfeeding | Not used; safety data is absent | Clear exclusion |
The short version: what is known about hexarelin is known mostly from men, and nothing in the research says how a woman's response differs.
Hexarelin for Women
What hexarelin is, in one paragraph
Hexarelin is a synthetic six-amino-acid peptide designed in the early 1990s as a more stable, more potent analogue of GHRP-6. It imitates ghrelin, the stomach hormone that signals hunger and tells the pituitary to release growth hormone, by binding the receptor GHS-R1a. It contains no growth hormone and does not act on estrogen, progesterone or the ovarian axis. Unlike the later selective growth hormone peptides, it also stimulates the pituitary cells that make ACTH and prolactin, so each dose brings a short pulse of those hormones alongside the growth hormone pulse.
Hexarelin for Women
What research has looked at, and who was in it
| Study | Who was in it | What it measured |
|---|---|---|
| Journal of Clinical Endocrinology and Metabolism, 1994 | Twelve healthy young volunteers | Growth hormone after single doses by four routes |
| Peptides, 1997 | Young adults | Prolactin, ACTH and cortisol after hexarelin and GHRP-2 |
| European Journal of Endocrinology, 1997 | Adults of different ages | How growth hormone, prolactin, ACTH and cortisol responses change with age |
| Journal of Clinical Endocrinology and Metabolism, 1998 | Healthy elderly volunteers | Sixteen weeks of twice-daily injections: response, body composition, bone |
| Journal of Endocrinological Investigation, 1999 | Seven male volunteers | Heart ejection fraction after one dose |
| Journal of Clinical Endocrinology and Metabolism, 2001 | Healthy young men | Growth hormone against ghrelin and GHRH |
| European Journal of Endocrinology, 2002 | Six young men | 24-hour hormone secretion on two or three daily injections |
| Clinical Endocrinology 1995, European Journal of Endocrinology 1996 | Short prepubertal children | Intranasal treatment for six to ten months |
The live summaries of the 1994, 1997 and 1998 studies do not describe results by sex. Where the sex of adult participants is stated, it is men. That is not unusual for 1990s endocrine pharmacology, and it means any statement about how hexarelin behaves in women is an inference from studies in men.
Why that matters: the one growth hormone trial that split by sex
In a 1997 randomised, placebo-controlled trial in the Journal of Clinical Endocrinology and Metabolism, ten women and nine men aged 55 to 71 injected a GHRH analogue nightly for sixteen weeks. Growth hormone, IGF-1 and skin thickness rose in both sexes, but lean mass and insulin sensitivity changed in men only. That trial did not use hexarelin, which acts on a different receptor. It does show that the growth hormone axis does not respond identically in women, which is a reason not to assume that results reported mainly in men apply to women. See sermorelin for women.
Body composition
The 1998 sixteen-week study is the only sustained adult course of subcutaneous hexarelin, and IGF-1, total body fat, lean body mass and bone mineral density did not change significantly. The growth hormone response to each dose fell by nearly half over the course and returned to baseline four weeks after stopping. Hexarelin is not a weight-loss medication.
Hexarelin for Women
What changes for women
The prolactin and cortisol pulse
This is the point most specific to women. Hexarelin raises prolactin with each dose; a 1997 study in Peptides found the rise smaller than that from TRH, while the ACTH and cortisol rise was similar in size to that from corticotropin-releasing hormone. In the 2002 study of young men, 24-hour prolactin and cortisol did not change, so each dose adds a short pulse rather than raising the daily total. That study was in men. Anyone with a known prolactin-related condition, or a condition affected by cortisol, should raise it at intake, because hexarelin is not the first choice for conditions sensitive to either hormone. Ipamorelin was designed to release growth hormone without that pulse; see ipamorelin vs hexarelin.
Pregnancy and breastfeeding
Hexarelin is not used in pregnancy or breastfeeding. Safety data is absent, and there is no clinical reason to accept the uncertainty. If you become pregnant on treatment, stop and contact your physician the same day. See can you take peptides while pregnant.
Trying to conceive
No study in the live research has measured fertility with hexarelin. Growth hormone signalling and reproductive hormones do interact, which is a reason for caution rather than a measured effect in either direction. Tell your physician if you are trying. See do peptides affect fertility.
The cycle and contraception
Hexarelin acts on the growth hormone axis, not the ovarian axis, and no study has looked at cycle effects. Because it raises prolactin briefly, report any cycle change to your physician rather than assuming it is unrelated. No interaction with hormonal contraception has been described, and none has been tested.
Cancer history, including breast cancer
Anything that raises growth hormone and IGF-1 carries the class cautions in approved growth hormone labelling, including a theoretical concern about existing tumours, and no data show hexarelin is exempt. A personal history of cancer, including breast, ovarian or endometrial cancer, belongs on the intake and is often a conversation with your oncologist before anything starts.
Blood sugar
Growth hormone reduces insulin sensitivity, and hexarelin adds a cortisol pulse. Diabetes or impaired glucose tolerance is raised at intake.
Hexarelin for Women
Menopause and sleep
What hexarelin does not do in menopause
Hexarelin has not been studied for any menopause symptom. It does not treat hot flashes, night sweats, genitourinary symptoms or bone loss, and it does not replace estrogen. The sixteen-week study found no change in bone mineral density. Pepti does not prescribe menopausal hormone therapy. More is in peptides for menopause and peptides for women.
Why the dose is at bedtime
The largest natural growth hormone pulse of the day arrives in the first hours of deep sleep, and a 2000 paper in JAMA described slow-wave sleep and that pulse declining together across adult life, in healthy men. A bedtime dose adds a pulse on top of the natural one; food intake was also reported to modulate the response. That is the rationale for the timing, not evidence that hexarelin improves sleep. No study has measured sleep as an outcome.
The 3am waking
Waking in the small hours is common in perimenopause and after. Night sweats wake people directly, falling progesterone removes a mildly sedating hormone, slow-wave sleep declines with age, and sleep apnea becomes more common after menopause. Which of those is driving the waking decides whether a growth hormone peptide is even the right category of answer. If sleep is the whole point, DSIP is aimed at it more directly.
Hexarelin for Women
What the evidence does not establish
- Anything specific to women. No study in the live research reports women separately.
- That hexarelin changes lean mass, body fat, bone density or weight. The one sustained course found no change.
- Any effect on menopause symptoms, the cycle or sex hormones.
- Any effect on sleep. It has not been measured.
- Long-term safety. The longest adult exposure on record is sixteen weeks.
Hexarelin for Women
Side effects
Nothing in the live research suggests the side-effect profile differs for women, though the studies that would show a difference have not been done.
| What is reported or relevant | What it usually means | What to do |
|---|---|---|
| Warmth or flushing after the injection | The effect people mention most | Usually settles; report it if marked |
| Hunger after a dose | On-target: it acts at the receptor ghrelin uses | Report it, particularly if weight is a concern |
| Transient headache, light-headedness | Short-lived | Report it if it persists |
| Injection-site redness or soreness | The commonest complaint with any injection | Rotate sites |
| A change in your cycle | Not described; worth reviewing given the prolactin pulse | Report it |
| Puffy hands or ankles, higher glucose readings | Growth hormone class risks | Message your care team |
| Facial or throat swelling, spreading rash, trouble breathing | A serious allergic reaction | Call 911 first, then tell your care team |
The fuller list, including the heart effect and desensitisation, is in hexarelin side effects. The WADA Prohibited List names hexarelin under S2.2.4, prohibited at all times, so it is off limits to women in tested sport; see is hexarelin banned in sports.
Hexarelin for Women
Where hexarelin stands with the FDA
Hexarelin is not in any category of the FDA's 503A nominations list updated 14 May 2026, was never in Category 2, and has never been reviewed by the Pharmacy Compounding Advisory Committee. The FDA has made no determination either way. Compounded medications are not FDA approved.
Hexarelin for Women
How Pepti supplies hexarelin
| Product | What is in it | Typical directions | Price |
|---|---|---|---|
| Hexarelin | 5 mL vial, hexarelin 2.5 mg/mL (12.5 mg per vial) | 0.25 mL (25 units) subcutaneously Monday through Friday nights at bedtime | $209/mo |
| Ipamorelin | 5 mL vial, 1 mg/mL (5 mg per vial) | Printed on your vial | $239/mo |
| Sermorelin | 5 mL vial, 2 mg/mL (10 mg per vial) | Printed on your vial | $229/mo |
At the typical direction, each 0.25 mL dose of the hexarelin vial is 0.625 mg (arithmetic from the 2.5 mg/mL strength, on a U-100 insulin syringe), and the vial holds 20 doses, about four weeks of weeknight dosing, which is why refills run every 28 days, one vial per fill. Your physician sets your directions after reviewing your intake, and they are printed on the vial. The growth hormone options are compared in sermorelin vs hexarelin and tesamorelin vs hexarelin.
Every price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. Vials arrive ready to use with sterile syringes and alcohol prep pads, shipped refrigerated with ice packs. Lot test results are at /quality/lab-results.
Hexarelin for Women
Where to get hexarelin prescribed
Hexarelin cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:
- Complete a free online intake covering your history, including pregnancy plans, cancer history, glucose and any prolactin or cortisol condition, your medications and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription.
- It ships refrigerated with your directions printed on the vial.
- Your physician stays reachable for questions and side effects.
Step by step: how to get hexarelin prescribed online. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
References
What this is based on.
References
- Ghigo E, Arvat E, Gianotti L et al.. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man · J Clin Endocrinol Metab (1994) · PMID 8126144
- Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy · J Clin Endocrinol Metab (1998) · PMID 9589671
- Rahim A, Shalet SM. Does desensitization to hexarelin occur? · Growth Horm IGF Res (1998) · PMID 10990150
- Ghigo E, Arvat E, Gianotti L et al.. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging · Eur J Endocrinol (1996) · PMID 8921821
- Klinger B, Silbergeld A, Deghenghi R et al.. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children · Eur J Endocrinol (1996) · PMID 8766941
- Laron Z, Frenkel J, Deghenghi R et al.. Intranasal administration of the GHRP hexarelin accelerates growth in short children · Clin Endocrinol (Oxf) (1995) · PMID 8548949
- Loche S, Cambiaso P, Carta D et al.. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects · J Clin Endocrinol Metab (1995) · PMID 7852535
- Massoud AF, Hindmarsh PC, Matthews DR, Brook CG. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity · Clin Endocrinol (Oxf) (1996) · PMID 8762732
- Maccario M, Veldhuis JD, Broglio F et al.. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans · Eur J Endocrinol (2002) · PMID 11888836
- Arvat E, di Vito L, Maccagno B et al.. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH · Peptides (1997) · PMID 9285939
- Ghigo E, Arvat E, Ramunni J et al.. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome · J Clin Endocrinol Metab (1997) · PMID 9253314
- Arvat E, Ramunni J, Bellone J et al.. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations · Eur J Endocrinol (1997) · PMID 9437229
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
Hexarelin for Women, answered.
It raises growth hormone in every adult group studied, but no study in the live research reports results for women separately, so how a woman's response compares is not known. No trial has measured an outcome a woman would notice.
No benefit has been established for women or men. The research describes a growth hormone pulse after each dose; the one sustained course found no change in lean mass, fat or bone density.
It has not been studied for any menopause symptom. It is not hormone therapy and does not treat hot flashes, night sweats or bone loss.
No. It is not a weight-loss medication, and the sixteen-week study found no change in body fat. For weight, the GLP-1 medications have the trial evidence.
It raises prolactin briefly with each dose. The measurements of 24-hour prolactin were made in young men, where the daily total did not change. A prolactin-related condition belongs on your intake.
It acts on the growth hormone axis, not the ovarian axis, and no study has looked at cycle effects. Because it raises prolactin briefly, report any change to your physician.
No. It is not used in either situation; safety data is absent.
No trial has compared them in women. Ipamorelin was designed to release growth hormone without the prolactin and cortisol pulse, which is why it is often preferred for longer courses. See ipamorelin vs hexarelin.
Most commonly warmth or flushing after the injection, hunger, a transient headache, light-headedness and injection-site redness. Nothing in the live research suggests these differ by sex.
At Pepti, hexarelin is $209 a month, all-in, covering medication, physician review, refill management and shipping.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.